STOCK TITAN

Sight Sciences, Inc. - SGHT STOCK NEWS

Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.

Sight Sciences, Inc. (SGHT) pioneers transformative ophthalmic devices for glaucoma and dry eye treatment, merging surgical precision with evidence-based therapeutic solutions. This page serves as the definitive source for SGHT-related news, offering stakeholders timely updates on advancements shaping eye care innovation.

Access press releases, clinical trial results, and regulatory milestones covering minimally invasive glaucoma surgery (MIGS) technologies like the OMNI Surgical System and the TearCare System for dry eye management. Our curated collection ensures professionals and investors stay informed about product approvals, peer-reviewed research, and strategic partnerships driving the company’s growth.

Explore updates across key areas including surgical device innovations, real-world clinical data, and regulatory filings. Each announcement is vetted for relevance, providing actionable insights into SGHT’s market position and technological leadership in interventional eyecare.

Bookmark this page for streamlined access to Sight Sciences’ latest developments. Regularly updated with authoritative content, it empowers users to track progress in ophthalmic treatment solutions backed by clinical validation and engineering excellence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
management
-
Rhea-AI Summary
Sight Sciences announces two-year results of the ROMEO study, demonstrating sustained and clinically meaningful reductions in IOP and glaucoma medication usage with the OMNI Surgical System technology. No serious adverse events were reported during the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.79%
Tags
none
-
Rhea-AI Summary
Sight Sciences announces results from a study on glaucoma medication use following MIGS procedures. Patients using OMNI Surgical System technology experienced a greater reduction in medication usage compared to other procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.28%
Tags
-
-
Rhea-AI Summary

Sight Sciences (Nasdaq: SGHT), a company dedicated to transforming eyecare through innovative technology, has announced its participation in the Bank of America Securities 2023 Health Care Conference in Las Vegas on May 10, 2023, at 3:40pm PT. The event will feature a fireside chat accessible via a live and archived webcast on the company’s investors page. Sight Sciences aims to enhance patient care with its products such as the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease. These minimally invasive solutions target the leading causes of eye issues, improving treatment outcomes over traditional methods.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
conferences
Rhea-AI Summary

Sight Sciences, Inc. (Nasdaq: SGHT), an innovative eyecare technology company, will report its financial results for Q1 2023 after market close on May 4, 2023. Management will host a conference call at 1:30 PM PT to discuss these results. Investors can access the live and archived webcast through the company’s website. Sight Sciences develops advanced solutions, including the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease, targeting prevalent eye diseases through non-invasive methods. These innovations aim to improve patient care and replace outdated treatments, positioning the company strongly in the eyecare market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
conferences earnings
-
Rhea-AI Summary

Sight Sciences Announces Surgical Glaucoma Investor Symposium

On April 13, 2023, Sight Sciences, Inc. (Nasdaq: SGHT) revealed plans for a Surgical Glaucoma Investor Symposium on May 5, 2023, in San Diego, CA, at 6:00 pm PT. The event will feature insights from leading glaucoma surgeons and remarks from the executive management team.

Attendance is limited and requires advance registration by April 21, 2023. A live webcast will be available on the investor relations website. Sight Sciences specializes in innovative eyecare solutions, focusing on minimally invasive treatments for glaucoma and other prevalent eye diseases.

Notable products include the OMNI® Surgical System for glaucoma management and the TearCare® System for dry eye disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences
-
Rhea-AI Summary

Sight Sciences (Nasdaq: SGHT) has announced the appointment of Alison "Ali" Bauerlein as Chief Financial Officer and Treasurer, effective April 3, 2023. Bauerlein brings extensive experience from her previous role at Inogen, where she oversaw financial operations during significant growth phases. CEO Paul Badawi expressed confidence in Bauerlein's ability to support the company's strategic plan and financial infrastructure as it aims for profitable growth. Bauerlein's background in medtech and her previous success in scaling organizations are expected to positively influence Sight Sciences' trajectory in the eyecare technology sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
management
Rhea-AI Summary

Sight Sciences, Inc. (Nasdaq: SGHT) successfully defeated all four patent invalidity challenges from Alcon and Ivantis regarding its Hydrus® Microstent technology. The U.S. Patent Office denied the petitions, confirming the validity of Sight Sciences’ patents. This decision follows a lawsuit filed in 2021, seeking damages and injunctive relief against Ivantis for patent infringement. A jury trial is set for April 8, 2024, in Wilmington, Delaware. Sight Sciences boasts a robust patent portfolio covering innovative approaches to glaucoma treatment and aims to vigorously defend its intellectual property.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
none
Sight Sciences, Inc.

Nasdaq:SGHT

SGHT Rankings

SGHT Stock Data

136.54M
40.43M
20.6%
54.74%
3.04%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MENLO PARK